MEDIPOST Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 290
- Market Cap
- -
- Website
- http://www.medi-post.co.kr
Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control
Phase 2
Active, not recruiting
- Conditions
- Knee Osteoarthritis
- Interventions
- Biological: SMUP-IA-01(low-dose)Biological: SMUP-IA-01(mid-dose)Drug: High Hyal Plus
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06798727
- Locations
- 🇰🇷
Seoul Nation University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Anam Hospita, Seoul, Korea, Republic of
Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis
Phase 2
Completed
- Conditions
- Knee Osteoarthritis
- Interventions
- Biological: SMUP-IA-01(low dose)Biological: SMUP-IA-01(mid dose)Drug: Active Control Group Sodium chloride
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT05182034
- Locations
- 🇰🇷
Seoul Nation University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Anam Hospita, Seoul, Korea, Republic of
Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial
Phase 1
Recruiting
- Conditions
- Knee Osteoarthritis
- Interventions
- Biological: SMUP-IA-01(low-dose)Biological: SMUP-IA-01(mid-dose)Biological: SMUP-IA-01(high-dose)
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04339504
- Locations
- 🇰🇷
Seoul national University Hospital, Seoul, Jongno-gu, Korea, Republic of
Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis
Phase 1
Completed
- Conditions
- Knee Osteoarthritis
- Interventions
- Biological: SMUP-IA-01(mid-dose)Biological: SMUP-IA-01(high-dose)Biological: SMUP-IA-01(low-dose)
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04037345
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
Phase 2
Active, not recruiting
- Conditions
- Bronchopulmonary DysplasiaBPD
- Interventions
- Biological: normal salineBiological: PNEUMOSTEM®
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04003857
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
Not Applicable
Completed
- Conditions
- Androgenic Alopecia
- Interventions
- Other: PlaceboOther: conditioned media of umbilical cord blood-derived stem cells
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT03676400
- Locations
- 🇰🇷
Dankook University Hospital, Cheonan, Chung Nam, Korea, Republic of
PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants
Phase 2
Completed
- Conditions
- Severe Bronchopulmonary Dysplasia
- Interventions
- Other: Placebo
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03392467
- Locations
- 🇰🇷
Asan medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: human umbilical cord blood derived mesenchymal stem cellsOther: Normal saline 2mL
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03172117
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: human umbilical cord blood derived mesenchymal stem cellsOther: Normal saline 2mL
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT02054208
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study
Completed
- Conditions
- Bronchopulmonary DysplasiaRespiratory Tract InfectionsPremature Birth of Newborn
- Interventions
- Biological: PNEUMOSTEM
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Medipost Co Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT02023788
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath